Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes

By Mikhail Nasser  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 6, 2008-06 ,pp. : 845-853

Informa Healthcare

Access to resources Recommend Favorite

The incretin system in the management of type 2 diabetes mellitus

By Stephens Jeffrey W  

Clinical Medicine, Vol. 10, Iss. 5, 2010-10 ,pp. : 491-495

Royal College Of Physicians

Access to resources Recommend Favorite

The Role of Oral Antidiabetic Agents and Incretin Mimetics in Type 2 Diabetic Patients with Non-Alcoholic Fatty Liver Disease

By  

Current Pharmaceutical Design, Vol. 20, Iss. 22, 2014-05 ,pp. : 3705-3715

Bentham Science Publishers

Access to resources Recommend Favorite

DGAT: Novel Therapeutic Target for Obesity and Type 2 Diabetes Mellitus

By  

Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Vol. 3, Iss. 4, 2003-12 ,pp. : 263-270

Bentham Science Publishers

Access to resources Recommend Favorite

Gastrin - A Potential Predictor of Response to Incretin Therapy in Diabetes Type 2 Patients

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 17, Iss. 4, 2017-11 ,pp. : 297-302

Bentham Science Publishers

Access to resources Recommend Favorite